Starpharma Holdings Limited (ASX:SPL, OCTQX:SPHRY) says it has achieved excellent progress in the recruitment for its VivaGelPhase 3 trials.
VivaGel is a gel-based formulation under clinical development, designed to treat and prevent the transmission of sexually transmitted infections such as Bacterial Vaginosis, genital herpes and HIV.
The biotechnology company says two Phase 3 trials, for the treatment of bacterial vaginosis, are now underway across more than 30 international sites and recruitment for these trials has recently passed the halfway mark.
Trials are believed to be well on track to be finished and reported this year after which the company will pursue regulatory approval for its VivaGel product.
Starpharma Holdings reported a net loss of $4.6 million in the first half of the 2012 financial year.
